Why Cybersecurity Stocks Are Trading Lower Today

Cybersecurity stocks including FireEye Inc (NASDAQ: FEYE), CrowdStrike Holdings Inc (NASDAQ: CRWD) and Zscaler Inc (NASDAQ: ZS) are

Cybersecurity stocks including FireEye Inc (NASDAQ:FEYE), CrowdStrike Holdings Inc (NASDAQ:CRWD) and Zscaler Inc (NASDAQ:ZS) are trading lower Friday after FireEye reported worse-than-expected second-quarter financial results. 

FireEye reported quarterly earnings of 9 cents per share, which was inline with estimates. The company reported quarterly revenue of $248 million, which came in below the estimate of $248.98 million. 

FireEye said it expects revenue in the third quarter to be in a range of $118 million to $122 million. 

The company noted that it repurchased $68 million in common stock during the second quarter.

“With the elevated threat environment, organizations are increasingly turning to Mandiant to proactively assess whether they are prepared and protected before a breach occurs,” said Kevin Mandia, CEO of FireEye.

Following the earnings report, Baird analyst Jonathan Ruykhaver downgraded FireEye from Outperform to Neutral and lowered the price target from $24 to $20.

Price Action: At last check Friday, FireEye was down 15.80% at $16.92, CrowdStrike was down 3.14% at $257.29 and Zscaler was down 3.12% at $239.94.

Photo by Pete Linforth from Pixabay.

Total
0
Shares
Related Posts
Read More

Earnings Outlook For Fuel Tech

Fuel Tech (NASDAQ:FTEK) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Fuel Tech will report an earnings per share (EPS) of $-0.02.

FTEK

Read More

Ipsen Announced Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma; Trial Met its Primary Endpoint and Key Secondary Endpoint

Ipsen (Euronext: IPN; ADR: IPSEY) announced the Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metasta

IPSEY

Read More

The Crisis In Housing, Part 4: Waiting For A Crypto Future

Compared to other sectors of the wider economy, the housing and mortgage industries have traditionally been slower to embrace cutting-edge technologies and digital solutions. A myriad of reasons explain this pokey response to evolving change, ranging from the sector’s conservative risk tolerance to a lack of standardization in many evolving technologies.

$DOGE